NFKB1 and Hepatic fibrosis: Groups treated with RPO at both tested levels (0.2 & 0.4 ml/rat) for two weeks post-induction of liver fibrosis significantly (P≤0.05) decreased TNF-α (422.6±35.71 and 372.7±25.93 ng/L), with percent of reduction (48.31% & 54.41%) respectively, IL-1β (301.9±23.22 and 292.4±11.12 pg/ml) respectively and showing a percent of reduction (60.79% and 62.02%) and NF-κβ (4869.4±490.68 and 4278.8±293.41 pg/mL, respectively) and showing a percent of reduction (81.2% and 83.47%, respectively) as compared to control positive group.